20 μg versus >20 μg estrogen combined oral contraceptives for contraception

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Gallo, Maria F ^a,c   Nanda, Kavita ^b   Grimes, David A ^b   Lopez, Laureen M ^b   Schulz, Kenneth F ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

Contraceptives, oral, combined *administration dosage; adverse effects ; Contraceptives, oral, hormonal *administration dosage; adverse effects ; Desogestrel administration dosage; adverse effects

Indexed keywords

ALBUMIN TC 99M COLLOID; ANULETTE 20; APRLL; CICLIDON 20; CICLOMEX 20; CYCLEANE 20; DESMIN 20; DESOGESTREL PLUS ETHINYLESTRADIOL; DESOREN 20; DIMINUT; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; EVE; FEDRA; FEMIANE; FEMILON; FEMINOL 20; FEMODETTE; GESTAGEN; GESTODENE; GYNERA 20; GYNERA 75; GYNOSTAT 20; GYNOVIN 20; LEOIS; LEROGIN 20; LEVONORGESTREL; LOESTRIN 1; LOESTRIN 21; LOESTRIN IRON 1; LOESTRIN IRON 20; LOETTE 21; LOGEST; LOVETTE; LOVINA 20; MARVELON 20; MELIANE LIGHT; MELODEN; MELODENE; MELODENE 15; MELODIA; MESTRANOL PLUS NORETHISTERONE; MICRODOSIS; MICROGEN; MICROGYNON 20; MICROGYNON 20 ED; MICROGYNON SUAVE; MINESSE; MINESTRIL 1; MINESTRIL 20; MINIFEM; MINIGESTE; MYRALON; NORETHISTERONE; NOVYNETTE; PHENACETIN; PRIMERA; SECURGIN; SEGURIN; SUAVURET; UNCLASSIFIED DRUG;

BIRTH CONTROL; BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTRACEPTION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GENETIC HETEROGENEITY; HEADACHE; HUMAN; MASTALGIA; MOOD CHANGE; OUTCOME ASSESSMENT; PREGNANCY RATE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TIME SERIES ANALYSIS; VOMITING; WEIGHT GAIN;

EID: 55049097108     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003989.pub3     Document Type: Review

References (105)

1. Akerlund 1993 {published data only} Akerlund M. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol. Acta Obstetricia et Gynecologica Scandinavica. Supplement 1997;164:63-5.
2. * Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 μg or 20 μg ethinyl oestradiol. British Journal of Obstetrics and Gynaecology 1993;100:832-8.
3. Appel 1987 {published data only} Appel TB, Kambi AA, Birdsall C, Christenson DA, Clark DO, DeKoning JR, et al.A comparison of a new graduated estrogen formulation with three constant-dosed oral contraceptives. Contraception 1987;35:523-32.
4. Basdevant 1993 {published data only} Basdevant A, Conard J, Pelissier C, Guyene TT, Lapousterle C, Mayer M, et al.Hemostatic and metabolic effects of lowering the ethinylestradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel. Contraception 1993;48:193- 204.
5. Bounds 1979 {published data only} Bounds W, Vessey M, Wiggins P. A randomized double-blind trial of two low dose combined oral contraceptives. British Journal of Obstetrics and Gynaecology 1979;86:325-9.
6. Brill 1996 {published data only} Brill K, Then A, Beisiegel U, Jene A, Wunsch C, Leidenberger F. Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 μg gestodene, on lipid metabolism in an open randomized trial. Contraception 1996;54:291-7.
7. Bruni 2000 {published data only} * Bruni V, Croxatto H, De La Cruz J, Dhont M, Durlot F, Fernandes MT, et al.A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives. Gestodene Study Group. Gynecological Endocrinology 2000;14:90-8.
8. Lacante P. A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel- containing oral contraceptives. Gynecological Endocrinology 1996;10:33-41.
9. Chavez 1999 {published data only} Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 μg/20 μg versus triphasic norethindrone/ethinylestradiol 500-750-1000 μg/35 μg: a multicenter, randomized, open-label study. The European Journal of Contraception and Reproductive Health Care 1999;4:75-83.
10. Endrikat 1997 {published data only} Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 μg gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997;55:131-7.
11. Endrikat 2001a {published data only} Endrikat J, Klipping C, Gerlinger C, Ruebig A, Schmidt W, Holler T, et al.A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 30 μg ethinyl estradiol and 75 μg gestodene on hemostatic variables, lipids, and carbohydrate metabolism. Contraception 2001;64:235-41.
12. Hampton 2001 {published data only} Burkman RT, Fisher AC, LaGuardia KD. Effects of low-dose oral contraceptives on body weight. Journal of Reproductive Medicine 2007;52:1030-4.
13. * Hampton RM, Short M, Bieber E, Bouchard C, Ayotte N, Shangold G, et al.Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception 2001;63:289-95.
14. Inauen 1991 {published data only} Inauen W, Stocker G, Haeberli A, Straub PW. Effects of low and high dose oral contraceptives on blood coagulation and thrombogenesis induced by vascular subendothelium exposed to flowing human blood. Contraception 1991;43:435-46.
15. Kirkman 1994 {published data only} Kirkman RJ. Clinical comparison of two low-dose oral contraceptives in women older than 30 years. Advances in Contraception 1991;7:63-76.
16. Kirkman RJ. Clinical comparison of two low dose oral contraceptives in women over 30 years of age. Advances in Contraception 1992;Vol. 8:170-1.
17. * Kirkman RJ, Pedersen JH, Fioretti P, Roberts HE. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception 1994;49:33-46.
18. Kirkman RJ, Pedersen JH, Fioretti P, Roberts HG. Comparison of acceptability and efficacy of low dose oral contraceptives containing gestodene or desogestrel. Advances in Contraception 1995;11:36-7.
19. Kluft 2006 {published data only} Kluft C, Endrikat J, Mulder SM, Gerlinger C, Heithecker R. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 μg ethinyl estradiol and a reference containing desogestrel and 30 μg ethinyl estradiol. Contraception 2006;73:336-43.
20. Reisman 1999 {published data only} Reisman H, Martin D, Gast MJ. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 μg levonorgestrel with 20 μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. American Journal of Obstetrics and Gynecology 1999;181 Suppl (5 Part 2):45-52.
21. Rosenberg 1999 {published data only} Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 μg and 35 μg estrogen preparations. Contraception 1999;60:321-9.
22. Skouby 2005 {published data only} Jespersen J, Endrikat J, Dusterberg B, Schmidt W, Gerlinger C, Wessel J, et al.A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 μg of ethinylestradiol and 100 μg of levonorgestrel with 30 μg of ethinylestradiol and 100 μg of levonorgestrel. Contraception 2005;72:98-104.
23. * Skouby SO, Endrikat J, Dusterberg B, Schmidt W, Gerlinger C, Wessel J, et al.A 1-yr randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgesterel. Contraception 2005;71:111-7.
24. Taneepanichskul 2002 {published data only} Taneepanichskul S, Kriengsinyot R, Jaisamrarn U. A comparison of cycle control, efficacy, and side effects among healthy Thai women between twolow-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene (Meliane) and 30 μg ethinylestradiol/75 μg gestodene (Gynera). Contraception 2002;66:407-9.
25. Teichmann 1995a {published data only} Teichmann AT, Brill K, Albring M, Schnitker J, Wojtynek P, Kustra E. The influence of the dose of ethinylestradiol in oral contraceptives on follicle growth. Gynecological Endocrinology 1995;9:299-305.
26. WHO 1982 {published data only} Task Force on Oral Contraceptives, WHO Special Programme of Research, Development and Research Training in Human Reproduction. A randomized, double-blind study of six combined oral contraceptives. Contraception 1982;25:231-41.
27. Winkler 1996a {published data only} Winkler UH, Schindler AE, Endrikat J, Dusterberg B. A comparative study of the effects of the hemostatic systemof two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol. Contraception 1996;53:75-84.
28. Akerlund 1994 {published data only} Akerlund M, Almstrom E, Hogstedt S, Nabrink M. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Acta Obstetricia et Gynecologica Scandinavica 1994;73:136-43.
29. Bassol 2000 {published data only} Bassol S, Alvarado A, Celis C, Cravioto MC, Peralta O, Montano R, et al.Latin American experience with two low-dose oral contraceptives containing 30 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol/150 μg desogestrel. Contraception 2000;62:131-5.
30. Bonnar 1992 {published data only} Bonnar J, Norris L, Sheppard BL. Comparative study of the effects of Mercilon, Marvelon and Femodene on blood coagulation, fibrinolysis and platelet function. Advances in Contraception 1992;8:171-2.
31. Caruso 2001 {published data only} Caruso S, Grillo C, Agnello C, Maiolino L, Intelisano G, Serra A. A prospective study evidencing rhinomanometric and olfactometric outcomes in women taking oral contraceptives. Human Reproduction 2001;16:2288-94.
32. Coenen 1995 {published data only} Coenen CM, Thomas CM, Borm GF, Hollanders JM, Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996;53:171-6.
33. * Coenen CM, Thomas CM, Borm GF, Rolland R. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives. International Journal of Fertility and Menopausal Studies 1995;40:92-7.
34. Creinin 2002 {published data only} Creinin MD, Lippman JS, Eder SE, Godwin AJ, Olson W. The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 μg ethinyl estradiol versus monophasic levonorgestrel/20 μg ethinyl estradiol. Contraception 2002;66:147-52.
35. Crosignani 1996 {published data only} Crosignani PG, Testa G, Vegetti W, Parazzini F. Ovarian activity during regular oral contraceptive use. Contraception 1996;54:271-3.
36. Egarter 1995 {published data only} Egarter C, Putz M, Strohmer H, Speiser P, Wenzl R, Huber J. Ovarian function during low-dose oral contraceptive use. Contraception 1995;51:329-33.
37. Elomaa 1998 {published data only} Elomaa K, Rolland R, Brosens I, Moorrees M, Deprest J, Tuominen J, et al.Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation. American Journal of Obstetrics and Gynecology 1998;179:41-6.
38. Endrikat 2001b {published data only} Endrikat J, Noah M, Gerlinger C, Bannemerschult R, Junge W, Ruebig A, et al.Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations. Contraception 2001;64:217-222.
39. Endrikat 2002 {published data only} Endrikat J, Klipping C, Cronin M, Gerlinger C, Ruebig A, Schmidt W, et al.An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 2002;65:215-21.
40. Fahraeus 1980 {published data only} Fahraeus L, Larsson-Cohn U, Wallentin L, Zador G. Plasma lipids, high density lipoproteins and SHBG during treatment with different combinations of ethinylestradiol and levonorgestrel [Abstract]. Acta Obstetricia et Gynecologica Scandinavica 1980; Vol. 93:72.
41. Ferreira 2001 {published data only} Ferreira ACP, Montes MBA, Franceschini SA, Toloi MRT. Effects of two oral contraceptives, containing 30 or 20 μg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women. International Journal of Fertility 2001;46:265-70.
42. Foulon 2001 {published data only} Foulon T, Payen N, Laporte F, Bijaoui S, Dupont G, Roland F, et al.Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. Contraception 2001;64:11-6.
43. Franchini 1995 {published data only} Franchini M, Caruso C, Nigrelli S, Poggiali C. Evaluation of body composition during low-dose estrogen oral contraceptives treatment. Acta Europaea Fertilitatis 1995;26:69-73.
44. Fruzzetti 1994 {published data only} Fruzzetti F, Ricci C, Fioretti P. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception 1994;49:579-92.
45. Huber 1995 {published data only} Huber JC. Clinical performance of OC class 20 μg. Advances in Contraception 1995;11:29-30.
46. Jespersen 1992 {published data only} Jespersen J, Petersen KR, Sidelmann J, Skouby SO. Unchanged hemostatic balance in young women during oral contraception with gestodene or desogestrel. Advances in Contraception 1992; Vol. 8: 171.
47. Klinger 1998 {published data only} Klinger G, Eick S, Klinger G, Pfister W, Graser T, Moore C, et al.Influence of hormonal contraceptives onmicrobial flora of gingival sulcus. Contraception 1998;57:381-4.
48. Larsson-Cohn 1981 {published data only} Larsson-Cohn U, Fahraeus L, Wallentin L, Zador G. Effects of the estrogenicity of levonorgestrel/ethinylestradiol combinations of the lipoprotein status. Acta Obstetricia et Gynecologica Scandinavica 1982;105:37-40.
49. * Larsson-Cohn U, Fahraeus L, Wallentin L, Zador G. Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. Fertility and Sterility 1981;35:172-9.
50. Lawson 1979 {published data only} Lawson JS, Yuliano SE, Pasquale SA, Osterman JJ. Optimum dosage of an oral contraceptive. American Journal of Obstetrics and Gynecology 1979;134:315-20.
51. Melis 1991 {published data only} Melis GB, Fruzzetti F, Nicoletti I, Ricci C, Lammers P, Atsma WJ, et al.A comparative study on the effects of a monophasic pill containing desogestrel plus 20 micrograms ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. Contraception 1991;43:23-31.
52. Melis 1995 {published data only} Melis GB, Paoletti AM, Murgia C. Low-dose OCs and hemostasis. Advances in Contraception 1995;11:30.
53. Miccoli 1989 {published data only} Miccoli R, Orlandi MC, Fruzzetti F, Giampietro O, Melis G, Ricci C, et al.Metabolic effects of three new low-dose pills: a six-month experience. Contraception 1989;39:643-52.
54. Mueck 2001 {published data only} Mueck AO, Seeger H, Petersen G, Schulte-Wintrop E, Wallwiener D. Effect of two oral contraceptives with different ethinyl estradiol and levonorgestrel concentrations on the urinary excretion of biochemical vasoactive markers. Contraception 2001;64:357-62.
55. Norris 1994 {published data only} Norris LA, Bonnar J. Effect of oestrogen dose on whole blood platelet activation in women taking newlow dose oral contraceptives. Thrombosis and Haemostasis 1994;72:926-30.
56. Norris 1996 {published data only} Norris LA, Bonnar J. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. British Journal of Obstetrics and Gynaecology 1996;103:261-7.
57. Oelkers 1995 {published data only} Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. The Journal of Clinical Endocrinology and Metabolism 1995;80:1816-21.
58. Paoletti 2000 {published data only} Paoletti AM, Orru M, Floris S, Mannias M, Vacca AM, Ajossa S, et al.Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women. Contraception 2000;61:259-63.
59. Pazzucconi 1991 {published data only} Pazzucconi F, Malavasi B, Galli G, Franceschini G, Calabresi L, Sirtori CR. Inhibition of antipyrine metabolism by low-dose contraceptives with gestodene and desogestrel. Clinical Pharmacology and Therapeutics 1991;49:278-84.
60. Petersen 1991 {published data only} Petersen KR, Skouby SO, Pedersen RG. Desogestrel and gestodene in oral contraceptives: 12 months' assessment of carbohydrate and lipoprotein metabolism. Obstetrics and Gynecology 1991;78:666-72.
61. Petersen 1993 {published data only} Petersen KR, Sidelmann J, Skouby SO, Jespersen J. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women. American Journal of Obstetrics and Gynecology 1993;168:32-8.
62. Rosenberg 1996 {published data only} Benagiano G. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol. International Journal of Fertility 1989;34:31-9.
63. * Rosenberg MJ, Waugh MS, Higgins JE. The effect of desogestrel, gestodene, and other factors on spotting and bleeding. Contraception 1996;53:85-90.
64. Song 1992 {published data only} Song S, Chen JK, Yang PJ, He ML, Li LM, Fan BC, et al.A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Contraception 1992;45:523-32.
65. Stanczyk 1999 {published data only} Stanczyk FZ, Ploszaj S, Gentzschein E, Qian D, Mishell DR Jr. Effect of oral contraceptives containing 20 and 35 micrograms ethinyl estradiol on urinary prostacyclin and thromboxane metabolite levels in smokers and nonsmokers. Contraception 1999;59:17-23.
66. Study Group 2003 {published data only} Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003;67:173-85.
67. Sulak 1999 {published data only} Sulak P, Lippman J, Siu C, Massaro J, Godwin A. Clinical comparison of triphasic norgestimate/35 μg ethinyl estradiol and monophasic norethindrone acetate/20 μg ethinyl estradiol. Cycle control, lipid effects, and user satisfaction. Contraception 1999;59:161-6.
68. Teichmann 1995b {published data only} Teichmann 1995. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. International Journal of Fertility 1995;40:98- 104.
69. Wendler 1995 {published data only} Wendler J, Siegert C, Schelhorn P, Klinger G, Gurr S, Kaufmann J, et al.The influence of Microgynon and Diane-35, two sub-fifty ovulation inhibitors, on voice function in women. Contraception 1995;6:343-8.
70. Westhoff 2005 {published data only} O'Connell KJ, Osborne LM, Westhoff C. Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. Contraception 2005;72:323-7.
71. Schafer JE, Osborne LM, Davis AR, Westhoff C. Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive. Contraception 2006;73:488-92.
72. * Westhoff C, Osborne LM, Schafer JE, Morroni C. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. Obstetrics & Gynecology 2005;106:89-96.
73. Wiegratz 2003 {published data only} * Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH, et al.Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003;67:25-32.
74. Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH, et al.Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. Contraception 2003;67:361-6.
75. Wiegratz I, Lee JH, Kutschera E, Bauer HH, von Hayn C, Moore C, et al.Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception 2002;65:223-9.
76. Winkler 1996b {published data only} Winkler UH, Holscher T, Schulte H, Zierleyn JP, Collet W, Schindler AE. Ethinylestradiol 20 versus 30 μg micrograms combined with 150 μg micrograms desogestrel: a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system. Gynecological Endocrinology 1996;10:265-71.
77. Anonymous 1996 Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996;347:1713-27.
78. Anonymous 2000 Anonymous 2000. Oral contraceptives and cardiovascular risk. Drug and Therapeutics Bulletin 2000;38:1-5.
79. Belsey 1986 Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception 1986;34:253-60.
80. Elstein 1994 Elstein M. Low dose contraceptive formulations: is further reduction in steroid dosage justified?. Advances in Contraception 1994;10:1-4.
81. Gerstman 1991 Gerstman BB, Gross TP, Kennedy DL, Bennett RC, Tomita DK, Stadel BV. Trends in the content and use of oral contraceptives in the United States, 1964-88. American Journal of Public Health 1991;81:90-6.
82. Guillebaud 1989 Guillebaud J. Practical prescribing of the combined oral contraceptive pill. In: Filshie M, Guillebaud J Filshie, John Guillebaud editor (s). Contraception: science and practice. London: Butterworth & Co., 1989:69-93.
83. Haag 1998 Haag U. Technologies for automating randomized treatment assignment in clinical trials. Drug Information Journal 1998;32:7-11.
84. Holt 1992 Holt VL, Daling JR, McKnight B, Moore D, Stergachis A, Weiss NS. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstetrics and Gynecology 1992;79:529-33.
85. IPPF 2008 International Planned Parenthood Federation. Directory of Hormonal Contraceptives. http://contraceptive.ippf.org (accessed 13 Mar 2008).
86. Juni 2002 Juni P, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and impact of language bias inmeta-analyses of controlled trials: empirical study. International Journal of Epidemiology 2002;31:115-23.
87. Lexchin 2003 Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal 2003;326:1167-70.
88. Maitra 2004 Maitra N, Kulier R, Bloemenkamp KWM, Helmerhorst FM, Gülmezoglu AM. Progestogens in combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD004861]
89. Miller 2001 Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstetrics and Gynecology 2001;98:771-8.
90. Mishell 2007a Mishell DR, Guillebaud J, Westhoff C, Nelson AL, Kaunitz AM, Trussell J, et al.Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception. Contraception 2007;75:4-10.
91. Mishell 2007b Mishell DR, Guillebaud J, Westhoff C, Nelson AL, Kaunitz AM, Trussell J, et al.Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception 2007;75:11-5.
92. Moher 2000 Moher D, Pham B, Klassen TP, Schulz KF, Berlin JA, Jadad AR, et al.What contributions do languages other than English make on the results of meta-analyses?. Journal of Clinical Epidemiology 2000;53:964-72.
93. Moher 2001 Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet 2001;357:1191-4.
94. Nelson 2007 Nelson AL. Combined oral contraceptives. In: Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D editor(s). Contraceptive Technology. 19th Edition. New York: Ardent Media, Inc., 2007:193-270.
95. Ness 2000 Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R, et al.Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. American Journal of Epidemiology 2000;152:233-41.
96. Rosenberg 1992 Rosenberg MJ, Long SC. Oral contraceptives and cycle control: a critical review of the literature. Advances in Contraception 1992;8 Suppl (1):35-45.
97. Rosenberg 1998 Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. American Journal of Obstetrics and Gynecology 1998;179:577-82.
98. Rothman 1998 Rothman KJ, Greenland S. Approaches to statistical analysis. In: Rothman KJ, Greenland S editor(s). Modern epidemiology. 2nd Edition. New York: Lippincott Williams and Wilkins, 1998:183-99.
99. Sackett 2000 Sackett DL, Strauss SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-based Medicine: How to Practice and Teach EBM. Second Edition. New York: Churchill Livingstone, 2000.
100. Schulz 2002 Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002;359:614-700.
101. Spona 1996 Spona J, Elstein M, Feichtinger W, Sullivan H, Ludicke F, Muller U, et al.Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996;54:71-7.
102. Thiboutot 2001 Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A randomized, controlled trial of a low-dose contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for acne treatment. Fertility and Sterility 2001;76:461-8.
103. Trussell 1998 Trussell J. Dynamics of reproductive behavior and population change. In: Hatcher RA, Trussell J, Stewart F, Cates W Jr, Stewart GK, Guest F, et al. editor(s). Contraceptive technology. 17th Edition. New York: Ardent Media Inc., 1998:745-77.
104. Wallach 2000 Wallach M, Grimes DA. Modern oral contraception. 1st Edition. Totowa, NJ: Emron, 2000.
105. Gallo 2005 Gallo MF, Nanda K, Grimes DA, Schulz KF. 20 mcg versus > 20 mcg Estrogen combined oral contraceptives for contraception. Contraception 2005;71:162-9.